SR One, a life sciences venture capital firm that years ago split from GSK, has raised more than $200 million for a growth opportunities fund, it told Endpoints News.
The fund is a “natural extension” to SR One’s existing work in the field, venture partner Jake Nunn said in a statement. It adds to the firm’s $500 million first fund and $600 million second fund, which was unveiled in March of last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.